Back to Search Results
Study Complete
Sponsor ID
20020778

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Sponsor ID
20020778
Clinicaltrials.gov ID
NCT00115414
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.

Additional Study Details

Phase
Phase 2
Product
pegfilgrastim
Type
Interventional
Masking
N/A
Enrollment
N/A
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Breast Cancer
  • Fever
    • Show more
  • Low White Blood Cell
    • Sex
    Assigned Female at Birth
    Trial Dates
    Apr 2003 - N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Breast cancer, previously untreated
    Exclusion Criteria:
    - Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, antiviral) within 72 hours of chemotherapy - Prior malignancy within the last 5 years, with the exception of surgically cured basal/squamous skin cell carcinoma, ductal carcinoma in situ of the breast and/or carcinoma of the cervix in situ - History of impaired cardiac status (e.g., severe heart disease, cardiomyopathy or congestive heart failure) - Major surgery within 2 weeks prior to randomization - Previous exposure to cytokines within two weeks prior - Concurrent use of other investigational agents